| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
|
| [2] |
|
| [3] |
Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022, 19(3): 151-172. DOI: 10.1038/s41571-021-00573-2.
|
| [4] |
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
|
| [5] |
Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/s1470-2045(18)30351-6.
|
| [6] |
Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial[J]. JAMA Oncol, 2020, 6(11): e204564. DOI: 10.1001/jamaoncol.2020.4564.
|
| [7] |
Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23(1): 77-90. DOI: 10.1016/S1470-2045(21)00604-5.
|
| [8] |
Qin S, Kudo M, Meyer T, et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial[J]. JAMA Oncol, 2023, 9(12): 1651-1659. DOI: 10.1001/jamaoncol.2023.4003.
|
| [9] |
Galle PR, Decaens T, Kudo M, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW[J]. J Clin Oncol, 2024, 42(17_suppl): LBA4008. DOI: 10.1200/jco.2024.42.17_suppl.lba4008.
|
| [10] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
|
| [11] |
Xu L, Zou C, Zhang S, et al. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors[J]. J Hematol Oncol, 2022, 15(1): 87. DOI: 10.1186/s13045-022-01307-2.
|
| [12] |
Shen KY, Zhu Y, Xie SZ, et al. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives[J]. J Hematol Oncol, 2024, 17(1): 25. DOI: 10.1186/s13045-024-01549-2.
|
| [13] |
Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2[J]. J Exp Med, 2012, 209(6): 1201-1217. DOI: 10.1084/jem.20112741.
|
| [14] |
Agdashian D, ElGindi M, Xie C, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2019, 68(4): 599-608. DOI: 10.1007/s00262-019-02299-8.
|
| [15] |
Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies[J]. J Exp Med, 2009, 206(8): 1717-1725. DOI: 10.1084/jem.20082492.
|
| [16] |
Decaens T, Yau T, Kudo M, et al. 965MO Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW[J]. Ann Oncol, 2024, 35: S657. DOI: 10.1016/j.annonc.2024.08.1025.
|
| [17] |
Sangro B, Chan SL, Kelley RK, et al. Four-year overall survival update from the phase Ⅲ HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma[J]. Ann Oncol, 2024, 35(5): 448-457. DOI: 10.1016/j.annonc.2024.02.005.
|
| [18] |
Rimassa L, Chan SL, Sangro B, et al. 947MO Five-year overall survival (OS) and OS by tumour response measures from the phase Ⅲ HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)[J]. Ann Oncol, 2024, 35: S656. DOI: 10.1016/j.annonc.2024.08.1007.
|
| [19] |
Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402(10408): 1133-1146. DOI: 10.1016/s0140-6736(23)00961-3.
|
| [20] |
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. DOI: 10.1016/s1470-2045(21)00252-7.
|
| [21] |
Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(4): 203-222. DOI: 10.1038/s41575-022-00704-9.
|
| [22] |
Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology, 2015, 148(7): 1383-1391. e6. DOI: 10.1053/j.gastro.2015.02.055.
|
| [23] |
Dai H, Tong C, Shi D, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase Ⅱ trial[J]. Oncoimmunology, 2020, 9(1): 1846926. DOI: 10.1080/2162402X.2020.1846926.
|
| [24] |
Ma R, Li Z, Antonio Chiocca E, et al. The emerging field of oncolytic virus-based cancer immunotherapy[J]. Trends Cancer, 2023, 9(2): 122-139. DOI: 10.1016/j.trecan.2022.10.003.
|
| [25] |
He C, Zhang Y, Lin X. Increased overall survival and decreased cancer-specific mortality in patients with hepatocellular carcinoma treated by transarterial chemoembolization and human adenovirus type-5 combination therapy: a competing risk analysis[J]. J Gastrointest Surg, 2018, 22(6): 989-997. DOI: 10.1007/s11605-018-3703-3.
|
| [26] |
Moehler M, Heo J, Lee HC, et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase Ⅱb trial (TRAVERSE)[J]. Oncoimmunology, 2019, 8(8): 1615817. DOI: 10.1080/2162402X.2019.1615817.
|
| [27] |
Yarchoan M, Gane EJ, Marron TU, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial[J]. Nat Med, 2024, 30(4): 1044-1053. DOI: 10.1038/s41591-024-02894-y.
|
| [28] |
Tang F, Tie Y, Tu C, et al. Surgical trauma-induced immunosuppression in cancer: recent advances and the potential therapies[J]. Clin Transl Med, 2020, 10(1): 199-223. DOI: 10.1002/ctm2.24.
|
| [29] |
Bakos O, Lawson C, Rouleau S, et al. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity[J]. J Immunother Cancer, 2018, 6(1): 86. DOI: 10.1186/s40425-018-0398-7.
|
| [30] |
Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218. DOI: 10.1016/S2468-1253(21)00427-1.
|
| [31] |
Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity[J]. Nat Cancer, 2021, 2(9): 891-903. DOI: 10.1038/s43018-021-00234-4.
|
| [32] |
Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 219-229. DOI: 10.1016/S2468-1253(21)00385-X.
|
| [33] |
Singal AG, Yarchoan M, Yopp A, et al. Neoadjuvant and adjuvant systemic therapy in HCC: current status and the future[J]. Hepatol Commun, 2024, 8(6): e0430. DOI: 10.1097/HC9.0000000000000430.
|
| [34] |
中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国抗癌协会肝癌专业委员会, 中国医师协会肝癌专业委员会, 等. 肝细胞癌新辅助及转化治疗中国专家共识(2023版)[J/CD]. 肝癌电子杂志, 2023, 10(4): 1-14.
|
| [35] |
He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13: 17588359211002720. DOI: 10.1177/17588359211002720.
|
| [36] |
Zhang TQ, Geng ZJ, Zuo MX, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase Ⅱ study[J]. Signal Transduct Target Ther, 2023, 8(1): 413. DOI: 10.1038/s41392-023-01663-6.
|
| [37] |
Wang K, Xiang YJ, Yu HM, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial[J]. Nat Med, 2024, 30(3): 708-715. DOI: 10.1038/s41591-023-02786-7.
|
| [38] |
Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023, 402(10415): 1835-1847. DOI: 10.1016/s0140-6736(23)01796-8.
|
| [39] |
Huang RSP, Haberberger J, Severson E, et al. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48, 782 cases[J]. Mod Pathol, 2021, 34(2): 252-263. DOI: 10.1038/s41379-020-00664-y.
|
| [40] |
Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma[J]. Nat Med, 2022, 28(8): 1599-1611. DOI: 10.1038/s41591-022-01868-2.
|
| [41] |
Monge C, Xie C, Steinberg SM, et al. Clinical indicators for long-term survival with immune checkpoint therapy in advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 507-512. DOI: 10.2147/JHC.S311496.
|
| [42] |
Myojin Y, Kodama T, Sakamori R, et al. Interleukin-6 is a circulating prognostic biomarker for hepatocellular carcinoma patients treated with combined immunotherapy[J]. Cancers, 2022, 14(4): 883. DOI: 10.3390/cancers14040883.
|
| [43] |
Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy-development and validation of the CRAFITY score[J]. J Hepatol, 2022, 76(2): 353-363. DOI: 10.1016/j.jhep.2021.09.035.
|
| [44] |
Pallozzi M, Di Tommaso N, Maccauro V, et al. Non-invasive biomarkers for immunotherapy in patients with hepatocellular carcinoma: current knowledge and future perspectives[J]. Cancers, 2022, 14(19): 4631. DOI: 10.3390/cancers14194631.
|
| [45] |
Yue C, Jiang Y, Li P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy[J]. Oncoimmunology, 2018, 7(7): e1438111. DOI: 10.1080/2162402X.2018.1438111.
|